WO2022208353 - ANTIGEN BINDING PROTEINS AND COMBINATIONS THEREOF
National phase entry:
Publication Number
WO/2022/208353
Publication Date
06.10.2022
International Application No.
PCT/IB2022/052897
International Filing Date
29.03.2022
Title **
[English]
ANTIGEN BINDING PROTEINS AND COMBINATIONS THEREOF
[French]
PROTÉINES DE LIAISON À L'ANTIGÈNE ET LEURS COMBINAISONS
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
GSK Medicines Research Centre
Gunnels Wood Road
Stevenage SG1 2NY, GB
Inventors
ROTH, Iris
259 East Grand Avenue
South San Francisco, California 94080, US
DEGENHARDT, Yan Y.
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
GUAN, Jun
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
HANCE, Kenneth William
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
MORLEY, Peter Joseph
Gunnels Wood Road
Stevenage SG1 2NB, GB
Priority Data
63/168,991
31.03.2021
US
63/275,651
04.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4248 | |
| EPO | Filing, Examination | 13145 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 5410 |
Total: 24001 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided are compositions for treating CD96 mediated diseases, and related methods.[French]
L'invention concerne des compositions pour le traitement de maladies médiées par CD96 et des méthodes associées.